IS7971A - Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema - Google Patents

Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema

Info

Publication number
IS7971A
IS7971A IS7971A IS7971A IS7971A IS 7971 A IS7971 A IS 7971A IS 7971 A IS7971 A IS 7971A IS 7971 A IS7971 A IS 7971A IS 7971 A IS7971 A IS 7971A
Authority
IS
Iceland
Prior art keywords
erythema
cave
diffuse
peptide
pharmaceutical preparation
Prior art date
Application number
IS7971A
Other languages
Icelandic (is)
Inventor
Cohen-Vered Sharon
Naftali Esmira
Weinstein Vera
Gilbert Adrian
Klinger Ety
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/000955 external-priority patent/WO2004064788A2/en
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of IS7971A publication Critical patent/IS7971A/en

Links

IS7971A 2004-01-14 2005-08-05 Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema IS7971A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/000955 WO2004064788A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
IS7971A true IS7971A (en) 2005-08-05

Family

ID=36701521

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7971A IS7971A (en) 2004-01-14 2005-08-05 Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema

Country Status (1)

Country Link
IS (1) IS7971A (en)

Similar Documents

Publication Publication Date Title
IS7972A (en) Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema
NO20073482L (en) Procedure for stabilizing antidement drug
DK2727583T3 (en) Drug carrier and drug carrier kit for inhibiting fibrosis
IL181779A (en) Class of therapeutic protein based molecules
ATE419769T2 (en) SYSTEM WITH CAPSULE WITH SEALANTS
DK2609947T3 (en) Plaster-like infusion set
IS8142A (en) Medication useful for the treatment of pain
EP1784219A4 (en) STABILIZING PREPARATIONS
EP1597276A4 (en) THERAPEUTIC MOLECULES
DK2058020T3 (en) Device for administering drug
NL1029015A1 (en) Therapeutic compounds.
DK2471807T3 (en) Long-acting polypeptides and methods for producing and administering the same
DK1765391T3 (en) BACTERIAL PREPARATIONS FOR THE TREATMENT OF CANCER
DE602004017700D1 (en) TRANSMUKOSEN ADMINISTRATION
NO20053119D0 (en) Pharmaceutical intestinal composition with fentanyl for intranasal administration.
DE602004009268D1 (en) connector support
ATE546141T1 (en) PHARMACEUTICAL INJECTION PREPARATION
ATE397618T1 (en) PEPTIDE CYCLIZATION
DK1809660T3 (en) THYMUS-SPECIFIC PROTEIN
DE112006001343A5 (en) patient support
EP1789064A4 (en) IMPROVED CANCER TREATMENT
DK1773829T3 (en) Aminotropan derivatives, their preparation and therapeutic uses
IS7971A (en) Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema
PL1753412T3 (en) Self-heating pharmaceutical patch
EP1767635A4 (en) FLUORESCENT PROTEIN